공고 • 21h
Synairgen plc Auditor Raises 'Going Concern' Doubt Synairgen plc filed its Annual on Aug 18, 2026 for the period ending Dec 31, 2025. In this report its auditor, BDO LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 공고 • Feb 27
Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical Study Synairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it. 공고 • Dec 10
Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical Study Synairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples. 공고 • Sep 05
Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024 Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October. 
